CSIMarket
 
Genomic Health Inc  (GHDX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 39
 Employees 6,395
 Revenues (TTM) (Millions $) 442
 Net Income (TTM) (Millions $) 57
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 19

Genomic Health Inc
Genomic Health Inc. is a precision medicine company that specializes in cancer diagnostics. It was founded in 2000 and is based in Redwood City, California. The company is dedicated to transforming cancer care through the development and commercialization of molecular diagnostic tests that provide physicians with a personalized approach to treating cancer patients.

Genomic Health's innovative tests use advanced genomic technology to analyze a patient's tumor to predict disease aggressiveness, response to treatment, and likelihood of recurrence. These tests help oncologists make more informed treatment decisions and provide patients with a more personalized approach to cancer care.

The company's flagship product is the Oncotype DX test, which is used to determine the likelihood of breast cancer recurrence and the benefit of chemotherapy after surgery. Oncotype DX analyzes the expression of 21 genes in a patient's tumor sample and generates a score that predicts the risk of recurrence. This test has been used to guide treatment decisions for over a million breast cancer patients worldwide.

In addition to the Oncotype DX test, Genomic Health has developed other diagnostic tests for prostate, colon, and lung cancers. The company is also developing new diagnostic products for other cancers, including melanoma, bladder cancer, and pancreatic cancer.

Genomic Health is committed to ensuring that its tests are accessible to all patients who need them. The company works closely with insurers, government agencies, and patient advocacy groups to ensure that its tests are covered by insurance and reimbursed at fair prices. Genomic Health also offers financial assistance programs to help low-income patients access its tests.

In 2019, Genomic Health was acquired by Exact Sciences, a leading precision oncology company. The two companies continue to work together to advance cancer diagnostics and treatment.


   Company Address: 301 Penobscot Drive Redwood City 94063 CA
   Company Phone Number: 556-9300   Stock Exchange / Ticker: NASDAQ GHDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Exagen Inc

Evanescence of Deficit: XGN Struggles with Weakness in Fourth Quarter Financial Report

Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.

Enzo Biochem Inc

Enzo Biochem Inc Revenue Plummeted during November to January 31, 2024 Period

Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low.
For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.

Ispecimen Inc

iSpecimen Inc. Faces Deficit on Weak Sales as Financial Period Ends December 31, 20232.

iSpecimen Inc. (Nasdaq: ISPC) is a pioneering online marketplace that connects scientists with healthcare specimen providers for research purposes. The company, headquartered in Lexington, Massachusetts, has recently announced that it will unveil its full-year financial results for the period ending December 31, 2023, on March 13, 2024. Stakeholders are eagerly awaiting the release of these results, as iSpecimen is globally recognized for its innovative platform that facilitates breakthrough discoveries and accelerates scientific advancements.
The previous fiscal span, from October to December 31, 2023, saw iSpecimen Inc. experience a deficit per share of $-0.33, compared to $-0.20 the previous year. This represents a growth in deficit per share from $-0.23 from the prior reporting season. Additionally, the company's revenue declined by -13.049% to $2.58 million from $2.96 million in the comparable reporting season a year before. Sequentially, revenue deteriorated by -7.296% from $2.78 million.

Maxcyte Inc

Maxcyte Inc. Sees Revenue Surge, But Fails to Reach Profitability Goals in Q4 2023

Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share.
Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.

Butterfly Network Inc

Butterfly Network Inc Surprises with Decreased Loss Per Share, Revenue Decline in Q4 2023

Butterfly Network Inc Reports Decreased Loss Per Share, Declining Revenue for Q4 2023
BURLINGTON, Mass. and NEW YORK - Butterfly Network, Inc. (NYSE: BFLY), a digital health company focused on portable, semiconductor-based ultrasound technology, announced its financial results for the quarter and year ended December 31, 2023. The company also provided an update on its business activities. Butterfly Network aims to make medical imaging more accessible through its innovative product offerings, software solutions, and educational programs.
For the financial period closing December 31, 2023, Butterfly Network reported a loss of $-0.21 per share, showing an improvement from the loss of $-0.31 per share in the previous year. However, there was an increased loss compared to the previous reporting period, from $-0.13 per share. The company's revenue declined by 14.346% to $17.08 million from $19.94 million, in the comparable reporting period a year prior. Nevertheless, sequentially, the revenue advanced by 11.013%, from $15.38 million.






 

Genomic Health Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Genomic Health Inc does not provide revenue guidance.

Earnings Outlook
Genomic Health Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com